Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

The speed at which several COVID-19 vaccines went from conception to receiving FDA and EMA approval for emergency use is an achievement unrivaled in the history of vaccine development. Mass vaccination efforts using the highly effective vaccines are currently underway to generate sufficient herd imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Chih-Yun, To, Albert, Wong, Teri Ann S., Lieberman, Michael M., Clements, David E., Senda, James T., Ball, Aquena H., Pessaint, Laurent, Andersen, Hanne, Furuyama, Wakako, Marzi, Andrea, Donini, Oreola, Lehrer, Axel T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570651/
https://www.ncbi.nlm.nih.gov/pubmed/34778744
http://dx.doi.org/10.1016/j.jvacx.2021.100126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570651/
https://www.ncbi.nlm.nih.gov/pubmed/34778744
http://dx.doi.org/10.1016/j.jvacx.2021.100126

Ejemplares similares